The greatest selection of Nancy Pelosi for the most profitable year after the dam report
The price of the Tempus Ai (NASDAQ: TEM) share price, which is noticeable in the former stock portfolio in the House of Representatives, Nancy Pelosi, which decreased by double numbers on Wednesday after the report of a short seller.
As of the time of the press, TEM was trading at $ 53.86, a decrease of more than 18 % a day. Despite the acute withdrawal, the arrow continues to rise by 61 % on an annual basis.
Why Tem’s shares disrupted
The sale was run by a report issued by Management Capital Point Point Point, which was accused of Tempus AI of amplifying its financial data, relying on questionable commercial practices, and highly dependent on marketing artificial intelligence without providing meaningful results.
One of the prominent report’s claims is that TEMPUS has achieved only $ 12.4 million of the prosecution’s revenue in 2024, only 1.8 % of its total revenue of $ 693.4 million. This number contrasts with the company’s high -tech brand.
The report also made suspicion of CEO Eric Levkovsky, noting his history with companies facing bankruptcy and accounting cases.
It also claimed potential sales, mysterious partnerships, and aggressive bills practices, especially using code 81479, which lacks strict organizational supervision.
Pelosi shares betting
Despite the controversy, Pelosi’s investment on January 14 in Tempus, which is estimated at 50,001 and 100,000 dollars through call options, is still more than weak, with increased gains by 105 % even after the last decline. The timing of the accurate trade of the Congress sparked the eyebrows earlier in the year with the rise of shares.
In the middle of the 2025 rally, SPRUCE POINT warned of a possible increase to 50 % to 60 %, casting suspicion of Tempus evaluation and urged caution.
Before reporting the short seller, Tempus AI was riding a wave of financial success. In the first quarter of 2025, the company reported the revenue of $ 255.7 million, an increase of 75.4 % on an annual basis. The total profit rose up, with 99.8 % jumped to 155.2 million dollars, indicating expansion margins.
Receive signals on the shares of the US Congress shares
Shares
Keep aware of the commercial activity of the members of the US Congress. The signal appears based on updates from the home disclosure reports, which teaches you the latest stock transactions.
The stock obtained another batch in late April after Tempus announced a $ 200 million partnership with Astrazneca and Pathos Ai. Long -term cooperation aims to develop a multimodal basis model for oncology, and take advantage of the huge Tempus for unspecified tumor data to push clinical and biological visions.
Distinctive image via Shutterstock
